GlassScriptPhysician profile
David Michael Smith
NPI 1306471297
$2,890.64
in general payments reported to CMS, 2019-2025
37 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.80 · 2023: $860 · 2024: $721 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,593 · Education: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,592.90 |
| Education | $281.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $418.25 | 2023-2025 | Keytruda, Keytruda Qlex, Welireg |
| Abbvie INC. | $378.95 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $258.51 | 2023-2025 | |
| Janssen Biotech, INC. | $185.84 | 2022-2025 | Talvey, Tecvayli, Rybrevant |
| Lilly USA, LLC | $144.38 | 2024-2025 | Verzenio, Jaypirca |
| Exelixis INC. | $133.40 | 2023 | Cabometyx |
| Genentech USA, INC. | $132.41 | 2023-2025 | Tecentriq, Venclexta, Polivy |
| Daiichi Sankyo INC. | $120.85 | 2023-2025 | Enhertu |
| Eisai INC. | $107.90 | 2023-2025 | |
| Seagen INC. | $94.79 | 2023 | Tukysa, Padcev |
| Incyte Corporation | $82.09 | 2023-2025 | Jakafi, Niktimvo |
| Glaxosmithkline, LLC. | $65.88 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| E.R. Squibb & Sons, L.L.C. | $65.16 | 2023-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $60.43 | 2023-2025 | Lynparza, Enhertu |
| Agios Pharmaceuticals, INC. | $56.98 | 2024-2025 | Pyrukynd |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $54.94 | 2024-2025 | |
| Amgen INC. | $54.41 | 2023 | Kyprolis, Blincyto, Prolia |
| Caris Mpi, INC. | $38.14 | 2025 | Mi Cancer Seek |
| Regeneron Healthcare Solutions, INC. | $35.60 | 2025 | Libtayo |
| Pfizer INC. | $33.34 | 2023-2024 | |
| Morphosys, US INC. | $31.25 | 2023 | Monjuvi |
| Amneal Pharmaceuticals LLC | $27.96 | 2025 | Alymsys |
| Array Biopharma INC | $26.43 | 2025 | Mektovi, Braftovi, Lorbrena |
| Pharmacosmos Therapeutics INC. | $26.42 | 2025 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $24.91 | 2025 | Fruzaqla |
| Beone Medicines USA, INC. | $23.53 | 2025 | Brukinsa |
| Fresenius Kabi USA, LLC | $21.66 | 2025 | Idacio |
| Stemline Therapeutics INC. | $21.48 | 2024 | Orserdu |
| Genzyme Corporation | $21.44 | 2025 | |
| Puma Biotechnology, INC. | $20.50 | 2025 | |
| Apellis Pharmaceuticals, INC. | $19.16 | 2025 | Empaveli |
| Kite Pharma, INC. | $18.90 | 2024 | Yescarta |
| Recordati_rare_diseases_inc. | $18.39 | 2024 | Sylvant |
| Bayer Healthcare Pharmaceuticals INC. | $17.97 | 2025 | |
| Kyowa Kirin, INC. | $17.86 | 2025 | |
| Deciphera Pharmaceuticals INC. | $15.62 | 2023 | Qinlock |
| Celgene Corporation | $14.91 | 2023 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.